{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "from dotenv import load_dotenv\n",
    "import os\n",
    "\n",
    "load_dotenv()\n",
    "\n",
    "api_key = os.getenv(\"GEMINI_API_KEY\")\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Here's a breakdown of Guideline-Directed Medical Therapy (GDMT) for Heart Failure with Reduced Ejection Fraction (HFrEF), outlining the medications and key considerations:\n",
      "\n",
      "**Core GDMT Medications**\n",
      "\n",
      "These medications have the strongest evidence base for improving survival and reducing hospitalizations in HFrEF.\n",
      "\n",
      "*   **Angiotensin Receptor-Neprilysin Inhibitor (ARNI)**:\n",
      "    *   **Sacubitril/Valsartan (Entresto)**:\n",
      "        *   **Mechanism:** Neprilysin inhibition increases natriuretic peptides, while valsartan blocks the angiotensin II receptor.\n",
      "        *   **Benefits:** Superior to ACE inhibitors in reducing mortality and hospitalization.\n",
      "        *   **Initiation:** Start at a low dose and titrate up as tolerated every 2-4 weeks.\n",
      "        *   **Contraindications:** History of angioedema with ACE inhibitors or ARBs, concurrent use of ACE inhibitors, pregnancy.\n",
      "*   **Beta-Blockers**\n",
      "    *   **Carvedilol (Coreg)**: Non-selective beta-blocker with alpha-1 blocking activity.\n",
      "    *   **Bisoprolol (Zebeta)**: Beta-1 selective blocker.\n",
      "    *   **Metoprolol Succinate (Toprol XL)**: Beta-1 selective blocker (extended-release formulation is crucial).\n",
      "        *   **Mechanism:** Reduce heart rate, blood pressure, and myocardial oxygen demand.  Also improve LV remodeling.\n",
      "        *   **Benefits:** Reduce mortality, hospitalization, and sudden cardiac death.\n",
      "        *   **Initiation:** Start at a very low dose and titrate up slowly (every 2-4 weeks). May see transient worsening of symptoms initially.\n",
      "        *   **Contraindications:** Symptomatic bradycardia, heart block (2nd or 3rd degree), severe hypotension, decompensated heart failure.\n",
      "*   **Mineralocorticoid Receptor Antagonists (MRAs)**\n",
      "    *   **Spironolactone (Aldactone)**: Non-selective MRA.\n",
      "    *   **Eplerenone (Inspra)**: Selective MRA.\n",
      "        *   **Mechanism:** Block aldosterone, reducing sodium and water retention, and preventing myocardial fibrosis.\n",
      "        *   **Benefits:** Reduce mortality and hospitalization.\n",
      "        *   **Initiation:** Start at a low dose and monitor potassium and renal function closely.\n",
      "        *   **Contraindications:** Hyperkalemia (K+ > 5.0 mEq/L), significant renal impairment (eGFR < 30 mL/min), concurrent use of strong CYP3A4 inhibitors (for eplerenone).\n",
      "*   **Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors**\n",
      "    *   **Dapagliflozin (Farxiga)**\n",
      "    *   **Empagliflozin (Jardiance)**\n",
      "        *   **Mechanism:** Inhibit SGLT2 in the proximal renal tubule, reducing glucose reabsorption and promoting glucosuria.  The mechanism of benefit in HF is not entirely understood, but it is independent of diabetes status.\n",
      "        *   **Benefits:** Reduce hospitalization for heart failure and cardiovascular death.\n",
      "        *   **Initiation:** Can be started at any point in the treatment course.\n",
      "        *   **Contraindications:** Severe renal impairment (check specific product labeling), type 1 diabetes (risk of DKA).\n",
      "\n",
      "**Other Medications Considered in Specific Situations**\n",
      "\n",
      "*   **Loop Diuretics**\n",
      "    *   **Furosemide (Lasix)**, **Bumetanide (Bumex)**, **Torsemide (Demadex)**\n",
      "        *   **Mechanism:** Promote sodium and water excretion, relieving congestion.\n",
      "        *   **Use:** Primarily for symptomatic relief of fluid overload.  Do not improve mortality.\n",
      "        *   **Considerations:** Use the lowest effective dose. Monitor electrolytes (especially potassium and magnesium) and renal function.\n",
      "*   **Hydralazine and Isosorbide Dinitrate (BiDil)**\n",
      "    *   **Mechanism:** Hydralazine is a direct arterial vasodilator; isosorbide dinitrate is a venodilator (nitric oxide donor).\n",
      "        *   **Benefits:** Shown to reduce mortality in self-identified Black patients with HFrEF when added to standard therapy.  Can also be used in patients who are unable to tolerate ACE inhibitors or ARBs.\n",
      "*   **Digoxin (Lanoxin)**\n",
      "    *   **Mechanism:** Positive inotrope; slows AV nodal conduction.\n",
      "        *   **Use:** May be considered for symptomatic relief in patients with persistent symptoms despite GDMT, particularly those with atrial fibrillation and rapid ventricular response. Does not improve mortality.\n",
      "        *   **Considerations:** Narrow therapeutic index. Monitor digoxin levels, renal function, and electrolytes.\n",
      "*   **Vericiguat (Verquvo)**\n",
      "    *   **Mechanism:** Soluble guanylate cyclase (sGC) stimulator, leading to increased cGMP production and vasodilation.\n",
      "        *   **Use:** May be considered in patients with worsening HFrEF despite GDMT, particularly after a recent heart failure hospitalization or need for IV diuretics. Modest benefit.\n",
      "*   **Ivabradine (Corlanor)**\n",
      "    *   **Mechanism:** Selective inhibitor of the If current in the sinoatrial node, reducing heart rate.\n",
      "        *   **Use:** May be considered in patients with stable symptomatic HFrEF who are in sinus rhythm with a resting heart rate ≥ 70 bpm despite being on a maximally tolerated beta-blocker dose (or in whom beta-blockers are contraindicated).\n",
      "\n",
      "**Important Considerations for GDMT**\n",
      "\n",
      "*   **Individualization:** Tailor treatment to the individual patient based on their specific symptoms, comorbidities, and tolerance of medications.\n",
      "*   **Up-titration:** Gradually increase doses of medications every 2-4 weeks as tolerated, aiming for target doses used in clinical trials.\n",
      "*   **Monitoring:** Closely monitor patients for adverse effects, electrolyte imbalances, renal function changes, and symptom improvement.\n",
      "*   **Team-Based Approach:** Optimal heart failure management involves a multidisciplinary team, including physicians, nurses, pharmacists, and other healthcare professionals.\n",
      "*   **Adherence:** Emphasize the importance of medication adherence and provide patient education to improve outcomes.\n",
      "*   **Device Therapy:** Consider implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT) in eligible patients.\n",
      "*   **Comorbidities:** Manage comorbidities such as hypertension, diabetes, coronary artery disease, and atrial fibrillation, as they can impact heart failure outcomes.\n",
      "*   **NYHA Functional Class:** GDMT is often guided by the patient's New York Heart Association (NYHA) functional class.\n",
      "*   **Shared Decision-Making:** Engage patients in shared decision-making, discussing the benefits and risks of different treatment options.\n",
      "\n",
      "This information provides a general overview of GDMT for HFrEF. Consult the latest guidelines from the American Heart Association (AHA), American College of Cardiology (ACC), and Heart Failure Society of America (HFSA) for the most up-to-date recommendations.\n"
     ]
    }
   ],
   "source": [
    "from openai import OpenAI\n",
    "\n",
    "client = OpenAI(\n",
    "    api_key=api_key,\n",
    "    base_url=\"https://generativelanguage.googleapis.com/v1beta/openai/\"\n",
    ")\n",
    "\n",
    "stream = client.chat.completions.create(\n",
    "    model=\"gemini-2.0-flash\",\n",
    "    n=1,\n",
    "    messages=[\n",
    "        {\"role\": \"system\", \"content\": \"You are a helpful assistant for medical resident physician education. As sophisticated users, they do not benefit from any disclaimers, e.g, no need to state, 'educational use only'.\"},\n",
    "        {\n",
    "            \"role\": \"user\",\n",
    "            \"content\": \"list the medications used for GDMT for CHF\"\n",
    "        }\n",
    "    ],\n",
    "    stream=True,\n",
    ")\n",
    "\n",
    "for response in stream:\n",
    "   print(response.choices[0].delta.content, end=\"\", flush=True)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Okay, here's a list of the medications used for Guideline-Directed Medical Therapy (GDMT) for Heart Failure:\n",
      "\n",
      "**Core GDMT Medications (Proven to Reduce Mortality & Morbidity):**\n",
      "\n",
      "*   **Angiotensin Receptor-Neprilysin Inhibitor (ARNI)**:\n",
      "    *   Sacubitril/Valsartan (Entresto)\n",
      "\n",
      "*   **Beta-Blockers:** (Specifically, these have demonstrated benefit)\n",
      "    *   Bisoprolol\n",
      "    *   Carvedilol (including Carvedilol CR)\n",
      "    *   Metoprolol Succinate (Toprol XL)\n",
      "\n",
      "*   **Mineralocorticoid Receptor Antagonists (MRAs)**: (Also known as Aldosterone Antagonists)\n",
      "    *   Spironolactone\n",
      "    *   Eplerenone\n",
      "\n",
      "*   **Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors**\n",
      "    *   Dapagliflozin\n",
      "    *   Empagliflozin\n",
      "\n",
      "**Other Medications Commonly Used in Heart Failure Management:**\n",
      "\n",
      "*   **Loop Diuretics:** (For Symptom Relief – Primarily Volume Overload)\n",
      "    *   Furosemide\n",
      "    *   Bumetanide\n",
      "    *   Torsemide\n",
      "    *   Ethacrynic Acid (less common, used for sulfa allergy)\n",
      "\n",
      "*   **Angiotensin-Converting Enzyme (ACE) Inhibitors:** (Used if ARNI is not tolerated or not available, less preferred)\n",
      "    *   Enalapril\n",
      "    *   Lisinopril\n",
      "    *   Ramipril, etc.\n",
      "\n",
      "*   **Angiotensin II Receptor Blockers (ARBs):** (Used if ACE inhibitors are not tolerated, less preferred than ARNI)\n",
      "    *   Valsartan\n",
      "    *   Losartan\n",
      "    *   Candesartan, etc.\n",
      "\n",
      "*   **Hydralazine and Isosorbide Dinitrate (H-ISDN):** (Specifically for African American patients with HFrEF, or those who cannot tolerate ACE/ARB/ARNI)\n",
      "\n",
      "*   **Digoxin:** (May be used for symptom control, particularly in patients with atrial fibrillation and rapid ventricular response)\n",
      "\n",
      "*   **Ivabradine:** (May be considered in patients with stable symptomatic HFrEF, LVEF ≤ 35%, in sinus rhythm with a heart rate ≥ 70 bpm at rest, who are on maximally tolerated GDMT)\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print(response.choices[0].message.content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Model(id='models/chat-bison-001', created=None, object='model', owned_by='google')\n",
      "Model(id='models/text-bison-001', created=None, object='model', owned_by='google')\n",
      "Model(id='models/text-bison-safety-recitation-off', created=None, object='model', owned_by='google')\n",
      "Model(id='models/text-bison-safety-off', created=None, object='model', owned_by='google')\n",
      "Model(id='models/text-bison-recitation-off', created=None, object='model', owned_by='google')\n",
      "Model(id='models/embedding-gecko-001', created=None, object='model', owned_by='google')\n",
      "Model(id='models/evergreen-custom', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-1.0-pro-latest', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-1.0-pro', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-pro', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-1.0-pro-001', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-1.0-pro-vision-latest', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-pro-vision', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-1.5-pro-latest', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-1.5-pro-001', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-1.5-pro-002', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-1.5-pro', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-1.5-flash-latest', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-1.5-flash-001', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-1.5-flash-001-tuning', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-1.5-flash', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-1.5-flash-002', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-1.5-flash-dark-launch', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-test-23', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-1.5-flash-8b', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-1.5-flash-8b-001', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-1.5-flash-8b-latest', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-1.5-flash-8b-exp-0827', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-1.5-flash-8b-exp-0924', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-2.0-flash-exp', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-2.0-flash', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-2.0-flash-001', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-2.0-flash-lite-preview', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-2.0-flash-lite-preview-02-05', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-2.0-pro-exp', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-2.0-pro-exp-02-05', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-exp-1206', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-tool-test', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-2.0-flash-thinking-exp-01-21', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-2.0-flash-thinking-exp', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-2.0-flash-thinking-exp-1219', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-2.0-flash-thinking-exp-no-thoughts', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-2.0-flash-001-bidi-test', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-2.0-flash-audiogen-rev17', created=None, object='model', owned_by='google')\n",
      "Model(id='models/gemini-2.0-flash-jarvis', created=None, object='model', owned_by='google')\n",
      "Model(id='models/learnlm-1.5-pro-experimental', created=None, object='model', owned_by='google')\n",
      "Model(id='models/embedding-001', created=None, object='model', owned_by='google')\n",
      "Model(id='models/text-embedding-004', created=None, object='model', owned_by='google')\n",
      "Model(id='models/aqa', created=None, object='model', owned_by='google')\n",
      "Model(id='models/imagen-3.0-generate-002', created=None, object='model', owned_by='google')\n",
      "Model(id='models/imagen-3.0-generate-002-exp', created=None, object='model', owned_by='google')\n",
      "Model(id='models/image-verification-001', created=None, object='model', owned_by='google')\n"
     ]
    }
   ],
   "source": [
    "models = client.models.list()\n",
    "for model in models:\n",
    "    print(model)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
